PHMs, Proteolysis Targeting Chimeras, Monovalent Degraders

We are also leveraging our knowledge of Targeted Protein Degradation and modulation to rapidly advance our clinical and preclinical stage programs. We focus on high impact targets, identifying clinically validated biological pathways with key proteins that drive the pathogenesis of multiple diseases that have been difficult to drug with conventional methods. Our initial programs target CDK7/9, GSPT1, CK1a, IKAROS, PDE4, KRAS and IL2 with the potential to address a broad range of therapeutic areas including oncology, inflammation and other diseases.

The BioTheryX name and logo are our trademarks. We also own the registered U.S. trademark for PHM® and PHMs™. The trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. We may have omitted the ® and ™ designations, as applicable, for the trademarks named in this presentation.


Our lead clinical candidate, BTX-A51, is an oral small molecule, multi-kinase inhibitor designed to block a specific leukemic stem cell target (CK1α) as well as super enhancer targets (CDK7/CDK9) preventing transcription of key oncogenic genes. This therapeutic mechanism entails activation of p53 (an important tumor suppressor) and its sustained stabilization by super-enhancer shutdown of Mdm2 (a protein degrader of p53), in combination with transcriptional shutdown of leukemia oncogenes, such as Myc and Mcl1.

Blocking CKIα, CDK7, and CDK9 augments and synergistically stabilizes p53 promoting the rapid killing of leukemia cells as well as leukemic stem cells. Pre-clinical results have been published in a peer-reviewed Cell journal, demonstrating BTX-A51’s favorable efficacy in animals.

Our Phase 1 clinical trial of BTX-A51 is currently ongoing and recruiting patients.

Patient Recruiting